CraniUS Therapeutics develops implantable systems for direct intracranial drug delivery, positioned at the intersection of neurosurgery, infusion technology, and CNS therapeutics. Its NeuroPASS platform is designed to provide durable access to brain tissue when systemic delivery is constrained by the blood-brain barrier. The program is investigational and is progressing through regulatory preparation, manufacturing scale-up, and product testing.

NeuroPASS embeds a cranial implant into the skull and connects it to intracranial catheters that deliver therapeutics to targeted regions. Delivery is pump-driven, refillable, and supported by wireless charging, enabling repeated dosing without externalized hardware. The approach aligns with convection-enhanced delivery, using pressure-driven infusion to extend distribution beyond diffusion-limited injection while keeping flow rate and dosing schedules adjustable.

The platform targets clinical use cases requiring repeated, localized administration, including brain cancer and other neurological conditions where regional targeting and sustained treatment matter. Implantation would occur in a surgical setting, with subsequent refills and dosing adjustments intended to fit into longitudinal care workflows. Within the BBB-access ecosystem, NeuroPASS represents a chronic local-delivery strategy that contrasts with non-invasive permeability approaches, with outcomes dependent on distribution control, infusion parameters, and catheter placement.